These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 25668262)

  • 21. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
    Umeh CC; Pérez A; Augustine EF; Dhall R; Dewey RB; Mari Z; Simon DK; Wills AM; Christine CW; Schneider JS; Suchowersky O
    PLoS One; 2014; 9(12):e112287. PubMed ID: 25486269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
    Simuni T; Fiske B; Merchant K; Coffey CS; Klingner E; Caspell-Garcia C; Lafontant DE; Matthews H; Wyse RK; Brundin P; Simon DK; Schwarzschild M; Weiner D; Adams J; Venuto C; Dawson TM; Baker L; Kostrzebski M; Ward T; Rafaloff G;
    JAMA Neurol; 2021 Mar; 78(3):312-320. PubMed ID: 33315105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Stocchi F; Rascol O; Hauser RA; Huyck S; Tzontcheva A; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt DJ;
    Neurology; 2017 Jun; 88(23):2198-2206. PubMed ID: 28490648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
    Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
    ; Schwarzschild MA; Ascherio A; Beal MF; Cudkowicz ME; Curhan GC; Hare JM; Hooper DC; Kieburtz KD; Macklin EA; Oakes D; Rudolph A; Shoulson I; Tennis MK; Espay AJ; Gartner M; Hung A; Bwala G; Lenehan R; Encarnacion E; Ainslie M; Castillo R; Togasaki D; Barles G; Friedman JH; Niles L; Carter JH; Murray M; Goetz CG; Jaglin J; Ahmed A; Russell DS; Cotto C; Goudreau JL; Russell D; Parashos SA; Ede P; Saint-Hilaire MH; Thomas CA; James R; Stacy MA; Johnson J; Gauger L; Antonelle de Marcaida J; Thurlow S; Isaacson SH; Carvajal L; Rao J; Cook M; Hope-Porche C; McClurg L; Grasso DL; Logan R; Orme C; Ross T; Brocht AF; Constantinescu R; Sharma S; Venuto C; Weber J; Eaton K
    JAMA Neurol; 2014 Feb; 71(2):141-50. PubMed ID: 24366103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
    Jankovic J; Watts RL; Martin W; Boroojerdi B
    Arch Neurol; 2007 May; 64(5):676-82. PubMed ID: 17502466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
    Hutchison RM; Fraser K; Yang M; Fox T; Hirschhorn E; Njingti E; Scott D; Bedell BJ; Kistner KM; Cedarbaum JM; Evans KC; Graham D; Martarello L; Mollenhauer B; Lang AE; Dam T; Beaver J
    Neurology; 2024 Mar; 102(5):e209137. PubMed ID: 38315945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
    Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
    J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.